Health 2011


Analysis: Is Pharma's big brand era over?

NEW YORK When drug sales reps come knocking in the future, they are increasingly likely to lavish their attentions on neurologists or cancer specialists than that old standby -- the local family doctor.


New headaches humble healthcare CEOs

NEW YORK A new generation of healthcare industry chiefs, faced with 21st century headaches, can't afford to get too comfortable.


Ending drug companies' addiction to price rises

NEW YORK Drug companies are dosing up on price increases to prop up stagnant sales, but will soon need to break that addiction as more medicines face generic competition.


U.S. patients picking Botox over preventive care

NEW YORK Americans are starting to see the doctor again, but more often for cosmetic procedures, such as Botox treatments, rather than cancer screening and other potentially life-saving preventive care.


Novartis girds for rival Regeneron eye drug

NEW YORK Novartis AG said it considers Regeneron Pharmaceuticals Inc's experimental eye drug a serious potential rival to its blockbuster Lucentis treatment and is gearing up for a marketing fight.


Sebelius upbeat on health exchanges

NEW YORK/WASHINGTON Most states likely will run their own medical insurance marketplaces or partner with neighbors to help expand coverage under the federal health overhaul, U.S. Health Secretary Kathleen Sebelius said on Wednesday.

Quotes from Reuters Health Summit on Wednesday

NEW YORK Top executives and officials from the healthcare industry joined Reuters reporters at the Health Summit in New York this week. Here is a list of top quotes:


Novartis grateful for J&J recalls

NEW YORK/ZURICH Demand for Novartis AG consumer health products has been bolstered by repeated recalls of Johnson & Johnson brands and the Swiss drugmaker expects to retain a chunk of the business when J&J brings its products back to market.

Drugmakers gear up to copy biotech drugs in U.S.

NEW YORK Plenty of industry players want a piece of the U.S. market for generic versions of complex biotech drugs, but winners are likely to need the marketing muscle of a big pharmaceutical company.


Analysis: Big Pharma strips down broken R&D engine

NEW YORK It's a lousy time to work in a drug lab, but the pink slips handed out to tens of thousands of pharmaceutical industry employees may have a silver lining for investors.


Becton device would improve glucose monitoring

NEW YORK Becton Dickinson & Co is developing needle technology to monitor blood sugar and deliver insulin that could bring the concept of an artificial pancreas for diabetics a step closer to reality, its chief executive said.